Relative affinity of CHI 621 for T-cell blasts of humans, rhesus, cynomolgus monkeys and dogs.
Novartis Pharma AG, Basel, Switzerland.
V F
VF
Quesniaux
C
C
Vedrine
C
C
Maurer
F
F
Grossmueller
H J
HJ
Schuurman
M H
MH
Schreier
K
K
Mueller
D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology* / Q000494:pharmacology; D000918:Antibody Specificity; D000077552:Basiliximab; D001667:Binding, Competitive; D002478:Cells, Cultured; D004285:Dogs; D006801:Humans; D007376:Interleukin-2 / Q000494:pharmacology; D007700:Kinetics; D008213:Lymphocyte Activation; D008252:Macaca fascicularis; D008253:Macaca mulatta; D051379:Mice; D015375:Receptors, Interleukin-2 / Q000096:biosynthesis*; D011993:Recombinant Fusion Proteins / Q000276:immunology / Q000494:pharmacology; D013601:T-Lymphocytes / Q000276:immunology*
D000911:Antibodies, Monoclonal; D007376:Interleukin-2; D015375:Receptors, Interleukin-2; D011993:Recombinant Fusion Proteins; D000077552:Basiliximab